Stephanie Gleicher1, Eric C Kauffman2,3, Leszek Kotula1,4, Gennady Bratslavsky1, Srinivas Vourganti1. 1. Department of Urology, SUNY Upstate Medical University, Syracuse, New York. 2. Departments of Urology and Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York. 3. Department of Urology, SUNY University of Buffalo, Buffalo, New York. 4. Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, New York.
Abstract
BACKGROUND: Patients with germline BRCA2 gene mutations (BRCA2mut) have more aggressive prostate cancer. Analysis of all reported germline BRCA2mut prostate cancer cases allows better understanding of the clinicopathologic features and survival outcomes of these men. METHODS: A systematic review was performed with the MEDLINE database to capture articles evaluating clinicopathologic characteristics of men with BRCA2mut associated prostate cancer. Inclusion criteria were at least five subjects, confirmation of BRCA2mut status, and data for at least 2 clinical parameters of disease. Meta-analysis was performed on outcomes data. Chi-squared tests were used to compare disease features among men undergoing formal versus ad hoc screening, as well as an age of diagnosis less than versus greater than 65 years. Rates of metastatic disease among BRCA2mut cases were compared to rates among non-carrier control subjects and the general population using the SEER database. RESULTS: Twelve out of 289 studies met our inclusion criteria, representing 261 BRCA2mut men. Among carriers, the median age at diagnosis was 62 years and median PSA was 15 ng/dl with 95% of men having a PSA>3. Over 40% of BRCA2mut patients had T3/T4 disease and over 25% were metastatic at presentation. Survival was worse in BRCA2mut men with prostate cancer when compared to non-BRCA2mut subjects. BRCA2mut carriers had significantly higher rates of metastatic disease (18%) versus non-carrier controls (8%) and the SEER population (4%). CONCLUSIONS: BRCA2mut carriers are more likely to have poor risk of prostate cancer at presentation and exhibit worse oncologic outcomes relative to non-carriers, including a fourfold increase in metastatic disease. Younger men and those undergoing formal screening present with less advanced disease which supports a need for earlier identification and screening protocols. Additionally, this population may benefit from alternative therapeutic paradigms. Prostate 76:1135-1145, 2016.
BACKGROUND:Patients with germline BRCA2 gene mutations (BRCA2mut) have more aggressive prostate cancer. Analysis of all reported germline BRCA2mut prostate cancer cases allows better understanding of the clinicopathologic features and survival outcomes of these men. METHODS: A systematic review was performed with the MEDLINE database to capture articles evaluating clinicopathologic characteristics of men with BRCA2mut associated prostate cancer. Inclusion criteria were at least five subjects, confirmation of BRCA2mut status, and data for at least 2 clinical parameters of disease. Meta-analysis was performed on outcomes data. Chi-squared tests were used to compare disease features among men undergoing formal versus ad hoc screening, as well as an age of diagnosis less than versus greater than 65 years. Rates of metastatic disease among BRCA2mut cases were compared to rates among non-carrier control subjects and the general population using the SEER database. RESULTS: Twelve out of 289 studies met our inclusion criteria, representing 261 BRCA2mut men. Among carriers, the median age at diagnosis was 62 years and median PSA was 15 ng/dl with 95% of men having a PSA>3. Over 40% of BRCA2mut patients had T3/T4 disease and over 25% were metastatic at presentation. Survival was worse in BRCA2mut men with prostate cancer when compared to non-BRCA2mut subjects. BRCA2mut carriers had significantly higher rates of metastatic disease (18%) versus non-carrier controls (8%) and the SEER population (4%). CONCLUSIONS: BRCA2mut carriers are more likely to have poor risk of prostate cancer at presentation and exhibit worse oncologic outcomes relative to non-carriers, including a fourfold increase in metastatic disease. Younger men and those undergoing formal screening present with less advanced disease which supports a need for earlier identification and screening protocols. Additionally, this population may benefit from alternative therapeutic paradigms. Prostate 76:1135-1145, 2016.
Authors: David S P Tan; Christian Rothermundt; Karen Thomas; Elizabeth Bancroft; Rosalind Eeles; Susan Shanley; Audrey Ardern-Jones; Andrew Norman; Stanley B Kaye; Martin E Gore Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544
Authors: Heather Thorne; Amber J Willems; Eveline Niedermayr; Ivan M Y Hoh; Jason Li; David Clouston; Gillian Mitchell; Stephen Fox; John L Hopper; Damien Bolton Journal: Cancer Prev Res (Phila) Date: 2011-07
Authors: David J Gallagher; Mia M Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Stadler; Samson W Fine; Victor Reuter; Michael Zelefsky; Michael J Morris; Howard I Scher; Robert J Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark E Robson; Kenneth Offit Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles Journal: BJU Int Date: 2010-09-14 Impact factor: 5.588
Authors: Lori J Pierce; Kelly-Anne Phillips; Kent A Griffith; Saundra Buys; David K Gaffney; Meena S Moran; Bruce G Haffty; Merav Ben-David; Bella Kaufman; Judy E Garber; Sofia D Merajver; Judith Balmaña; Amichay Meirovitz; Susan M Domchek Journal: Breast Cancer Res Treat Date: 2010-04-22 Impact factor: 4.872
Authors: Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles Journal: Br J Cancer Date: 2011-09-27 Impact factor: 7.640
Authors: Elena Castro; Chee Goh; David Olmos; Ed Saunders; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Nadiya Mahmud; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Emma Sawyer; Rosemary Wilkinson; Audrey Ardern-Jones; Steve Ellis; Debra Frost; Susan Peock; D Gareth Evans; Marc Tischkowitz; Trevor Cole; Rosemarie Davidson; Diana Eccles; Carole Brewer; Fiona Douglas; Mary E Porteous; Alan Donaldson; Huw Dorkins; Louise Izatt; Jackie Cook; Shirley Hodgson; M John Kennedy; Lucy E Side; Jacqueline Eason; Alex Murray; Antonis C Antoniou; Douglas F Easton; Zsofia Kote-Jarai; Rosalind Eeles Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544
Authors: A Mitra; C Fisher; C S Foster; C Jameson; Y Barbachanno; J Bartlett; E Bancroft; R Doherty; Z Kote-Jarai; S Peock; D Easton; R Eeles Journal: Br J Cancer Date: 2008-01-08 Impact factor: 7.640
Authors: Patrick G Pilié; Anna M Johnson; Kristen L Hanson; Megan E Dayno; Ashley L Kapron; Elena M Stoffel; Kathleen A Cooney Journal: Cancer Date: 2017-06-28 Impact factor: 6.860
Authors: Siddhartha Yadav; Steven N Hart; Chunling Hu; David Hillman; Kun Y Lee; Rohan Gnanaolivu; Jie Na; Eric C Polley; Fergus J Couch; Manish Kohli Journal: JCO Precis Oncol Date: 2019-09-17
Authors: Beth N Peshkin; Mary Kate Ladd; Claudine Isaacs; Hannah Segal; Aryana Jacobs; Kathryn L Taylor; Kristi D Graves; Suzanne C O'Neill; Marc D Schwartz Journal: J Cancer Educ Date: 2021-02 Impact factor: 2.037
Authors: Vivek L Patel; Evan L Busch; Tara M Friebel; Angel Cronin; Goska Leslie; Lesley McGuffog; Julian Adlard; Simona Agata; Bjarni A Agnarsson; Munaza Ahmed; Kristiina Aittomäki; Elisa Alducci; Irene L Andrulis; Adalgeir Arason; Norbert Arnold; Grazia Artioli; Brita Arver; Bernd Auber; Jacopo Azzollini; Judith Balmaña; Rosa B Barkardottir; Daniel R Barnes; Alicia Barroso; Daniel Barrowdale; Muriel Belotti; Javier Benitez; Birgitte Bertelsen; Marinus J Blok; Istvan Bodrogi; Valérie Bonadona; Bernardo Bonanni; Davide Bondavalli; Susanne E Boonen; Julika Borde; Ake Borg; Angela R Bradbury; Angela Brady; Carole Brewer; Joan Brunet; Bruno Buecher; Saundra S Buys; Santiago Cabezas-Camarero; Trinidad Caldés; Almuth Caliebe; Maria A Caligo; Mariarosaria Calvello; Ian G Campbell; Ileana Carnevali; Estela Carrasco; Tsun L Chan; Annie T W Chu; Wendy K Chung; Kathleen B M Claes; Gemo Study Collaborators; Embrace Collaborators; Jackie Cook; Laura Cortesi; Fergus J Couch; Mary B Daly; Giuseppe Damante; Esther Darder; Rosemarie Davidson; Miguel de la Hoya; Lara Della Puppa; Joe Dennis; Orland Díez; Yuan Chun Ding; Nina Ditsch; Susan M Domchek; Alan Donaldson; Bernd Dworniczak; Douglas F Easton; Diana M Eccles; Rosalind A Eeles; Hans Ehrencrona; Bent Ejlertsen; Christoph Engel; D Gareth Evans; Laurence Faivre; Ulrike Faust; Lídia Feliubadaló; Lenka Foretova; Florentia Fostira; George Fountzilas; Debra Frost; Vanesa García-Barberán; Pilar Garre; Marion Gauthier-Villars; Lajos Géczi; Andrea Gehrig; Anne-Marie Gerdes; Paul Gesta; Giuseppe Giannini; Gord Glendon; Andrew K Godwin; David E Goldgar; Mark H Greene; Angelica M Gutierrez-Barrera; Eric Hahnen; Ute Hamann; Jan Hauke; Natalie Herold; Frans B L Hogervorst; Ellen Honisch; John L Hopper; Peter J Hulick; KConFab Investigators; Hebon Investigators; Louise Izatt; Agnes Jager; Paul James; Ramunas Janavicius; Uffe Birk Jensen; Thomas Dyrso Jensen; Oskar Th Johannsson; Esther M John; Vijai Joseph; Eunyoung Kang; Karin Kast; Johanna I Kiiski; Sung-Won Kim; Zisun Kim; Kwang-Pil Ko; Irene Konstantopoulou; Gero Kramer; Lotte Krogh; Torben A Kruse; Ava Kwong; Mirjam Larsen; Christine Lasset; Charlotte Lautrup; Conxi Lazaro; Jihyoun Lee; Jong Won Lee; Min Hyuk Lee; Johannes Lemke; Fabienne Lesueur; Annelie Liljegren; Annika Lindblom; Patricia Llovet; Adria Lopez-Fernández; Irene Lopez-Perolio; Victor Lorca; Jennifer T Loud; Edmond S K Ma; Phuong L Mai; Siranoush Manoukian; Veronique Mari; Lynn Martin; Laura Matricardi; Noura Mebirouk; Veronica Medici; Hanne E J Meijers-Heijboer; Alfons Meindl; Arjen R Mensenkamp; Clare Miller; Denise Molina Gomes; Marco Montagna; Thea M Mooij; Lidia Moserle; Emmanuelle Mouret-Fourme; Anna Marie Mulligan; Katherine L Nathanson; Marie Navratilova; Heli Nevanlinna; Dieter Niederacher; Finn C Cilius Nielsen; Liene Nikitina-Zake; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Kai-Ren Ong; Ana Osorio; Claus-Eric Ott; Domenico Palli; Sue K Park; Michael T Parsons; Inge Sokilde Pedersen; Bernard Peissel; Ana Peixoto; Pedro Pérez-Segura; Paolo Peterlongo; Annabeth Høgh Petersen; Mary E Porteous; Miguel Angel Pujana; Paolo Radice; Juliane Ramser; Johanna Rantala; Muhammad U Rashid; Kerstin Rhiem; Piera Rizzolo; Mark E Robson; Matti A Rookus; Caroline M Rossing; Kathryn J Ruddy; Catarina Santos; Claire Saule; Rosa Scarpitta; Rita K Schmutzler; Hélène Schuster; Leigha Senter; Caroline M Seynaeve; Payal D Shah; Priyanka Sharma; Vivian Y Shin; Valentina Silvestri; Jacques Simard; Christian F Singer; Anne-Bine Skytte; Katie Snape; Angela R Solano; Penny Soucy; Melissa C Southey; Amanda B Spurdle; Linda Steele; Doris Steinemann; Dominique Stoppa-Lyonnet; Agostina Stradella; Lone Sunde; Christian Sutter; Yen Y Tan; Manuel R Teixeira; Soo Hwang Teo; Mads Thomassen; Maria Grazia Tibiletti; Marc Tischkowitz; Silvia Tognazzo; Amanda E Toland; Stefania Tommasi; Diana Torres; Angela Toss; Alison H Trainer; Nadine Tung; Christi J van Asperen; Frederieke H van der Baan; Lizet E van der Kolk; Rob B van der Luijt; Liselotte P van Hest; Liliana Varesco; Raymonda Varon-Mateeva; Alessandra Viel; Jeroen Vierstraete; Roberta Villa; Anna von Wachenfeldt; Philipp Wagner; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Greet Wieme; Siddhartha Yadav; Drakoulis Yannoukakos; Sook-Yee Yoon; Cristina Zanzottera; Kristin K Zorn; Anthony V D'Amico; Matthew L Freedman; Mark M Pomerantz; Georgia Chenevix-Trench; Antonis C Antoniou; Susan L Neuhausen; Laura Ottini; Henriette Roed Nielsen; Timothy R Rebbeck Journal: Cancer Res Date: 2019-11-13 Impact factor: 13.312